SCHEMBL679260

SCHEMBL679260

Nc1ccc(Oc2cc3cn[nH]c3cc2-c2ccncc2)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.59
ROCK1 Q13464 2/20 0.47
ROCK2 O75116 3/20 0.44
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
HIF1A Q16665 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CLK1 P49759 1/20 0.42
TRPA1 O75762 3/20 0.39
PIK3CA P42336 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
NTRK1 P04629 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680251 0.88 FGFR1 (0.45) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL680227 0.86 KDM4E (0.46) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL680260 0.86 TLR8 (0.46) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL680323 0.85 TLR8 (0.44) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL680692 0.83 TLR8 (0.41) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL680202 0.83 TLR8 (0.46) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL678942 0.82 TLR8 (0.54) TLR8ROCK1ROCK2MAPTALDH1A1
SCHEMBL680953 0.77 ROCK2 (0.44) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL680325 0.77 KDM4E (0.38) TLR8ROCK1ROCK2KDM4EMEN1
SCHEMBL8325182 0.74 KDM4E (0.58) ROCK1ROCK2KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC TLR8 3920/4885ROCK1 1269/4885ROCK2 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.